Beladerma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 117,781 | 249,872 | 304,024 | 668,240 | 916,045 | 970,733 | 1,016,752 | 937,319 |
| Profit before tax | 3,456 | 32,612 | 14,232 | 155,147 | 277,209 | 237,138 | 199,627 | -51,149 |
| Net profit | 3,456 | 30,940 | 11,991 | 131,418 | 235,566 | 201,082 | 169,253 | -72,102 |
| Equity | 2,965 | 33,905 | 45,895 | 177,313 | 194,057 | 231,615 | 234,515 | 107,458 |
| Liabilities | 145,730 | 131,463 | 114,296 | 89,205 | 91,414 | 86,075 | 68,137 | 93,321 |
| Non-current assets | 98,792 | 92,615 | 69,298 | 143,351 | 121,509 | 159,075 | 93,012 | 43,566 |
| Current assets | 49,658 | 72,391 | 89,846 | 122,512 | 162,004 | 158,355 | 204,719 | 155,866 |
| Total assets | 148,450 | 165,006 | 159,144 | 265,863 | 283,513 | 317,430 | 297,731 | 199,432 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 196,837 | 272,617 | 168,026 |
| Social insurance contributions | - | - | - | - | - | 51,590 | 80,527 | 95,243 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +544.1% | +112.1% | +21.7% | +119.8% | +37.1% | +6.0% | +4.7% | -7.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 2.3% | 18.8% | 7.5% | 49.4% | 83.1% | 63.3% | 56.8% | -36.2% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 116.6% | 91.3% | 26.1% | 74.1% | 121.4% | 86.8% | 72.2% | -67.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 2.9% | 12.4% | 3.9% | 19.7% | 25.7% | 20.7% | 16.6% | -7.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 2.9% | 13.1% | 4.7% | 23.2% | 30.3% | 24.4% | 19.6% | -5.5% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 49.2 | 3.9 | 2.5 | 0.5 | 0.5 | 0.4 | 0.3 | 0.9 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 39,260 | 69,732 | 41,934 | 72,899 | 77,961 | 74,196 | 75,783 | 69,005 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Beladerma - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-05-16 | 2025-05-25 | 260.99 |
| 2022-07-25 | 2022-08-03 | 0.32 |
| 2022-06-16 | 2022-07-03 | 60.35 |
| 2021-11-16 | 2021-12-05 | 0.01 |
| 2021-10-18 | 2021-11-07 | 0.01 |
| 2021-09-16 | 2021-10-04 | 0.01 |
Beladerma - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Beladerma, UAB (code 304406478) is a Private Limited Liability Company engaged in medical specialists activities. In 2025, the company generated EUR 937.3K in revenue, which was 7.8% lower year on year and 3.4% below the 2023 level. Profitability weakened sharply over the three-year period: net profit fell from EUR 201.1K in 2023 to EUR 169.3K in 2024, before turning into a EUR 72.1K loss in 2025. The profit margin therefore declined from 20.7% in 2023 to 16.6% in 2024 and -7.7% in 2025. The latest year also shows a pre-tax loss of EUR 51.1K. Total assets decreased from EUR 317.4K in 2023 to EUR 199.4K in 2025, while equity dropped to EUR 107.5K and liabilities increased to EUR 93.3K. The equity ratio stood at 53.9% and debt-to-equity at 0.87. Asset turnover was 4.70x, and revenue per employee reached EUR 72.1K, while profit per employee was negative at EUR 5.5K.